Metastatic colorectal cancer research hub
34 indexed studies · 13 currently recruiting
- ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer
This study is looking at new ways to treat advanced bowel cancer (colorectal cancer that has spread). It combines existing treatments with new drugs to see if they work better together. The aim is to find safer and more effective options for patients.
France · Italy · Spain - active not recruitingPHASE3
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
This study, KRYSTAL-10, is for people with advanced bowel cancer that has a specific genetic change (KRAS G12C). It compares a combination of new drugs, MRTX849 and cetuximab, against standard chemotherapy to see which works better for those who have already had initial treatment.
United States · Argentina · Australia - ongoing, recruitingTherapeutic exploratory (Phase II)
Multicenter, open-label, randomized, 2-arm, phase II study to evaluate the efficacy and safety of cetuximab plus irinotecan rechallenge compared with investigator's choice of therapy in the third-line setting in ctDNA genomically selected patients with metastatic colorectal cancer (CITRIC Study)
This study looks at a new treatment for advanced bowel cancer that has spread. It compares two approaches: a drug combination called cetuximab and irinotecan, versus standard care. Doctors want to see which is more effective and safer for patients whose cancer has specific genetic markers.
Spain - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixeddose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer
This study is testing a new combination medicine (relatlimab-nivolumab) for advanced bowel cancer that has spread. It compares it to existing treatments (Lonsurf or Stivarga) to see if it helps people live longer and improves their quality of life.
Belgium · Spain · France - authorisedTherapeutic confirmatory (Phase III)
Randomized study to compare first-line treatment with either continuous or intermittent cetuximab plus FOLFIRI in patients with RAS/BRAF-wild-type metastatic colorectal cancer (mCRC): AIO-KRK-0524 / FIRE-11
This study looks at different ways to give cetuximab with other drugs (FOLFIRI) for advanced bowel cancer that has spread. It wants to see if giving cetuximab continuously or in breaks affects how well the treatment works and patients' quality of life.
Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff
This study compares a new medicine, Telisotuzumab Adizutecan, with a standard treatment (Lonsurf plus Bevacizumab) for advanced bowel cancer that has spread. It focuses on patients whose cancer has a specific protein called c-Met. The aim is to find out which treatment is safer and more effective.
Germany · Poland · France - authorisedTherapeutic confirmatory (Phase III)
C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
This study is looking at a new medicine called PF-08634404 for people with bowel cancer that has spread. It compares this new medicine combined with standard chemotherapy to another combination often used, Bevacizumab with chemotherapy, to see which works better and is safer.
Spain · Belgium · France - active not recruitingPHASE2
iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
This study looks at a new combination of immunotherapy (Nivolumab and Relatlimab) for advanced bowel cancer that has spread. It focuses on patients whose cancer stopped responding to previous treatments, hoping to find new options.
United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
Evaluation of treatment PERSOnalization based on its therapeutic monitoring in patients with metastatic colorectal cancer treated with regorafenib
This study looks at how different levels of a cancer medicine called Stivarga (regorafenib) in the blood affect how well it works for people with advanced bowel cancer. Researchers want to find the best amount of medicine for each patient to improve their treatment.
France - recruitingPHASE3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
This study is for people with advanced bowel cancer that has spread and has a specific gene change called KRAS p.G12C. It compares a new combination of treatments to standard treatment to see if it can better stop the cancer from growing.
United States · Argentina · Australia - authorisedTherapeutic exploratory (Phase II)
VINORELBINE INHIBITS ONCOGENIC FUNCTIONS OF MKK3: A NEW THERAPEUTIC OPPORTUNITY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
This study is looking at a new way to treat bowel cancer that has spread. It uses a medicine called Vinorelbine to see if it can shrink tumours. Researchers want to find out how many patients' tumours get smaller and if the treatment helps people live longer and feel better.
Italy - recruitingPHASE2
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
This study is testing a new combination of medicines for advanced bowel cancer. It aims to see how safe and effective a new drug, telisotuzumab adizutecan, is when given with standard treatments. The study will look at side effects and whether the cancer activity changes.
United States · Australia · Austria - active not recruitingPHASE3
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study looks at new drug combinations for advanced bowel cancer that has spread. It compares nivolumab alone, nivolumab with ipilimumab, and standard chemotherapy to see which works best for patients whose cancer has specific features (dMMR/MSI-H).
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
This study looks at new treatments (BNT314 and BNT327) combined with standard chemotherapy for advanced bowel (colorectal) cancer. It aims to see if this combination is safe and helps shrink or slow cancer growth, especially for patients who haven't responded well to previous treatments.
United States · Germany · Japan - active not recruitingPHASE3
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
This study is testing a new combination treatment for advanced bowel cancer. It compares a new medicine (S95005) with an existing one (capecitabine), both given with bevacizumab. The aim is to see if the new combination works better for patients who can't have intensive chemotherapy.
Argentina · Australia · Austria - recruitingPHASE1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
This study looks at new treatments for bowel cancer that has spread. We want to see if these targeted medicines or immunotherapy are safe and work well for people whose cancer has specific genetic features, which we call biomarkers.
United States · Australia · Canada - recruitingPHASE2
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
This study is testing new treatments for a type of advanced bowel cancer that has spread. It compares a new drug called Volrustomig combined with standard chemotherapy and another drug (FOLFIRI and Bevacizumab) against the standard treatment alone, to see if adding Volrustomig is safe and effective.
United States · Australia · Canada - ongoing, recruitingPhase I and Phase II (Integrated)- Other
Z0011001-A PHASE 1/2, OPEN-LABEL, MULTI-CENTER STUDY OF ZN-c3 ADMINISTERED IN COMBINATION WITH ENCORAFENIB AND CETUXIMAB IN ADULTS WITH METASTATIC COLORECTAL CANCER
This study is testing a new combination of medicines for people with bowel cancer that has spread. We want to see if a new drug called Azenosertib, given with two existing drugs (Encafenib and Cetuximab), is safe and helps shrink the cancer. This is an early-stage study.
Poland · Spain · Germany - not yet recruiting
18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
This study looks at using a special type of scan, called a PET/CT, to see how well chemotherapy is working for people with advanced bowel cancer. We want to find out if these scans can show very early on whether treatment is helping, which could allow doctors to adjust treatment sooner if needed.
France - recruitingPHASE1, PHASE2
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
This early-stage study is testing a new type of immunotherapy called CC-38 for people with advanced bowel cancer or prostate cancer. It uses your own immune cells to try and fight the cancer. We want to see if this treatment is safe and effective.
Germany - active not recruitingPHASE2
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients
This study compares two drug combinations, FOLFIRINOX with Panitumumab and mFOLFOX6 with Panitumumab, for people with advanced bowel cancer. It's for patients whose cancer cells have specific genetic features (RAS and B-RAF wild-type).
France - active not recruitingPHASE1
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
This study looks at new treatments for advanced bowel cancer that has spread. It tests a new vaccine (ATP128), a drug called BI 754091, and sometimes another vaccine (VSV-GP128), both alone and in combinations, to see if they are safe and how well people tolerate them.
United States · Belgium · Germany - recruitingPHASE2
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
This study is testing two new drug combinations for advanced bowel cancer that has spread, but not actively to the liver. It aims to see if a new combination of two medicines, Fruquintinib and Tislelizumab, works better than standard treatment for this type of cancer.
Austria · Germany - recruitingPHASE2
Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
This study is looking at two different medicine combinations for bowel cancer that has spread. It compares panitumumab with trifluridine/tipiracil against bevacizumab with trifluridine/tipiracil, to see which works better as a first treatment.
Germany - active not recruitingPHASE2
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
This study looks at combining three medicines for advanced bowel cancer that has spread. It compares a new combination therapy (encorafenib, cetuximab, and pembrolizumab) with pembrolizumab alone for patients who haven't had treatment yet and have specific gene changes.
United States · Australia · Belgium - recruitingNA
Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer
This study looks at a new test called Oncogramme® to help doctors choose the best first treatment for advanced bowel cancer. The goal is to find treatments that work better for each person, cause fewer side effects, and improve their quality of life.
France - ongoing, recruitingTherapeutic exploratory (Phase II)
PEMBROLIZUMAB IN MMR-PROFICIENT METASTATIC COLORECTAL CANCER PHARMACOLOGICALLY PRIMED TO TRIGGER DYNAMIC HYPERMUTATION STATUS - THE ARETHUSA TRIAL
This study looks at a new way to treat advanced bowel cancer that has spread. It combines existing chemotherapy with an immunotherapy drug, pembrolizumab, hoping to make the immunotherapy more effective for people whose cancer hasn't responded to previous treatments.
Italy - recruitingPHASE2
Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.
This study looks at a new way to treat bowel cancer that has spread only to the liver and can't be removed with surgery. We're testing a combination of medicines (FOLFOXIRI and bevacizumab) to see if it can shrink the tumours enough so they can be operated on, aiming for a cure.
Canada - recruitingNA
A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
This study looks at people in the UK with a specific type of advanced bowel cancer (colorectal cancer) called BRAFV600E-mutated. Researchers are collecting blood samples and health information to better understand how this cancer behaves and to find effective treatments.
France - ongoing, recruitingTherapeutic exploratory (Phase II)
An open-label phase II prospective clinical trial to investigate safety, tolerability, maximum tolerated dose and anti-tumor effect for SCO-101 in combination with FOLFIRI as a safe and efficient treatment modality in metastatic or advanced colorectal cancer (mCRC) patients with acquired FOLFIRI resistant cancer disease
This study looks at a new drug, SCO-101, combined with standard FOLFIRI chemotherapy for advanced bowel cancer that has stopped responding to FOLFIRI. Researchers want to see if the combination is safe, what dose works best, and if it helps shrink tumours.
Spain - authorisedTherapeutic confirmatory (Phase III)
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
This study is looking at a new treatment called ivonescimab, given with standard chemotherapy (FOLFOX), for bowel cancer that has spread. We compare it to another treatment (bevacizumab) also with FOLFOX, to see which works best at stopping the cancer from growing.
Belgium · Italy · Spain - recruitingPHASE1, PHASE2
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This study is testing a new drug, ART0380, for people with advanced cancer. It aims to find the safest dose, understand side effects, and see how well it works, both alone and with other treatments like gemcitabine or irinotecan.
United States · France · Spain - authorisedTherapeutic exploratory (Phase II)
Impact of Biweekly and Triweekly Dosing Regimens on Progression-Free Survival in First-Line FOLFIRI Treatment of Metastatic Colorectal Cancer: A Non-Inferiority Study (FIR-DIR)
This study looks at different ways to give a common chemotherapy treatment (FOLFIRI) for advanced bowel cancer. Researchers want to see if giving it less often works just as well at keeping the cancer under control, while hopefully making treatment easier for patients.
Hungary - authorised (with conditions)Human Pharmacology (Phase I)- Other
PHASE Ib STUDY WITH THE COMBINATION OF LB−100 (PP2A INHIBITOR) AND AZENOSERTIB (WEE1 INHIBITOR) IN PATIENTS WITH METASTATIC COLORECTAL CANCER The COLLEE trial
This study is called COLLEE and is looking at two new medicines, LB-100 and azenosertib, for people with bowel cancer that has spread. We want to see if this combination is safe and how well it works to treat the cancer.
Netherlands